摘要
目的:系统评价扶正化瘀胶囊联合核苷类抗病毒药物治疗慢性乙型肝炎肝纤维化的有效性和安全性。方法:计算机检索中国生物医学文献数据库、万方数据资源系统、中国学术期刊全文数据库、中文科技期刊数据库、PubMed、EMBase,纳入符合标准的随机对照试验(RCT),并采用RevMan5.0软件进行Meta分析。结果:共纳入10项RCT,合计792例慢性乙型肝炎患者。Meta分析结果显示:玻璃酸在治疗24、48周时,试验组均优于对照组,差异有统计学意义[MD=-65.80,95%CI(-90.88,-40.73)、MD=-82.40,95CI%(-140.99,-23.81)];层黏连蛋白在治疗24、48周时,试验组均优于对照组,差异有统计学意义[MD=-29.08,95%CI(-36.57,-21.59)、MD=-68.89,95CI%(-107.45,-30.33)];Ⅲ型前胶原在治疗24周时,试验组优于对照组,差异有统计学意义[MD=-27.70,95%CI(-47.86,-7.55)],在48周时,试验组也优于对照组,但差异无统计学意义[MD=-61.69,95%CI(-124.50,1.12)];Ⅳ型胶原在治疗24、48周时,试验组均优于对照组,差异有统计学意义[MD=-27.77,95%CI(-36.18,-19.36)、MD=-57.58,95CI%(-104.42,-10.74)]。2组安全性评价差异无统计学意义(P<0.05)。结论:扶正化瘀胶囊联合核苷类抗病毒药物治疗慢性乙型肝炎肝纤维化疗效优于单用核苷类抗病毒药物,未见肝、肾功能不良反应,但受纳入文献质量限制,以上结论尚需要高质量的临床试验进一步证实。
OBJECTIVE：To evaluate the efficacy and safety of Fuzheng huayu capsule combined with nucleoside antiviral drugs for chronic hepatitis B liver fibrosis.METHODS：Retrieved from CBD,Wanfang database,CSJD,CNKI,PubMed,EMBase and related journals,literatures meeting inclusion criteria were collected.Meta-analysis was performed by RevMan 5.0 software.RESULTS：10 RCT were included,involving 792 cases of chronic hepatitis B.Results of Meta-analysis showed：after treatment of 24 and 48 weeks,hyaluronic acid in the experimental group were better than the control group,the differences were statistically significant [MD=-65.80,95%CI（-90.88,-40.73）,MD=-82.40,95%CI（-140.99,-23.81）],and Laminin in the experimental group were better than the control group,the differences were statistically significant [MD=-29.08,95%CI（-36.57,-21.59）,MD=-68.89,95%CI（-107.45,-30.33）];After the treatment of 24 weeks,procollagen type Ⅲ in the experimental group was better than the control group,the differences were statistically significant [MD=-27.70,95%CI（-47.86,-7.55）],the experimental group was still better than the control group at 48 weeks,but the difference was not statistically significant [MD=-61.69,95%CI（-124.50,1.12）];After the treatment of 24 and 48 weeks,collagen type Ⅳ（C Ⅳ） in the experimental group were better than the control group,the differences were statistically significant [MD=-27.77,95%CI（-36.18,-19.36）,MD=-57.58,95%CI（-104.42,-10.74）].There were no statistically significant in both group of safty.CONCLUSION：The effect of Fuzheng huayu capsules combined with nucleoside antiviral drug is better than antiviral nucleoside antiviral drug alone in the treatment of chronic hepatitis B liver fibrosis.And adverse effect of liver and kidney hardly appear,but limited by the quality of included studies,the above conclusions still need high-quality clinical trials for further confirmation.
出处
《中国药房》
CAS
CSCD
北大核心
2011年第36期3382-3386,共5页
China Pharmacy
基金
国家自然科学基金资助项目(30671846)
